13 Sep 2017
N+1 Singer - Alliance Pharma - Interim results in line with expectations
Alliance Pharma’s interim results are in line with expectations, as flagged in the update in July. The group’s international growth brands delivered a solid performance with Kelo-cote™ sales increasing 52% and MacuShield™ up 67% to £6.2m and £3.4m respectively. Cash generation was strong and net debt continues to decrease. Unfortunately Diclectin® failed to gain approval in the UK by the MHRA post the period end. Whilst disappointing, the group still has growth opportunities in its product portf ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Alliance Pharma - Interim results in line with expectations
Alliance Pharma plc (APH:LON) | 36.8 0.1 0.4% | Mkt Cap: 199.0m
- Published:
13 Sep 2017 -
Author:
Sheena Berry -
Pages:
3
Alliance Pharma’s interim results are in line with expectations, as flagged in the update in July. The group’s international growth brands delivered a solid performance with Kelo-cote™ sales increasing 52% and MacuShield™ up 67% to £6.2m and £3.4m respectively. Cash generation was strong and net debt continues to decrease. Unfortunately Diclectin® failed to gain approval in the UK by the MHRA post the period end. Whilst disappointing, the group still has growth opportunities in its product portf ....